Chronic granulomatous disease: Difference between revisions
From IDWiki
(added DDx) |
m (Text replacement - " species]]" to "]]") |
||
(3 intermediate revisions by the same user not shown) | |||
Line 10: | Line 10: | ||
==Clinical Manifestations== |
==Clinical Manifestations== |
||
*Recurrent infections |
*Recurrent infections |
||
**Catalase-positive organisms, including [[Staphylococcus aureus]], [[Burkholderia cepacia]], [[Serratia marcescens]], [[Nocardia]], and [[Aspergillus]] |
|||
* |
**CGD is the highest-risk group for [[invasive aspergillosis]] |
||
*Granuloma formation, often in the GI and GU tracts and may precede other clinical symptoms |
|||
== |
==Differential Diagnosis== |
||
* |
*Other [[Primary immunodeficiency|primary immunodeficiencies]] |
||
** |
**[[MPO deficiency]], which will have an abnormal DHR test but largely asymptomatic unless concurrent [[diabetes mellitus]] |
||
** |
**[[Hyper-IgE syndrome]], though ''Aspergillus'' will be more typically pulmonary |
||
** |
**IRAK4/MyD88 deficiency, which won't have fungal infections and improves with age |
||
** |
**Humoral immunodeficiencies, such as [[CVID]] or [[Bruton tyrosine kinase deficiency]], though they tend to have more infections with encapsulated organisms and will have abnormal quantitative immunoglobulins |
||
* |
*[[Inflammatory bowel disease]] |
||
* |
*[[Cystic fibrosis]] |
||
*[[Sarcoidosis]], which will cause granuloma formation but shouldn't increase risk of infection |
|||
* [[Sarcoidosis]] |
|||
== |
==Diagnosis== |
||
* |
*The diagnosis is confirmed with the dihydrohodamine-123 (DHR-123) test |
||
==Management== |
==Management== |
||
Line 36: | Line 38: | ||
**Possibly also [[interferon-γ]] |
**Possibly also [[interferon-γ]] |
||
== |
==Further Reading== |
||
* |
*Considerations in the Diagnosis of Chronic Granulomatous Disease. ''J Pediatric Infect Dis Soc''. 2018;7(S1):S6-S11. doi: [https://doi.org/10.1093/jpids/piy007 10.1093/jpids/piy007] |
||
[[Category:Pediatrics]] |
[[Category:Pediatrics]] |
Latest revision as of 16:56, 2 February 2022
Background
- Primary immunodeficiency of neutrophils leading to recurrent infections with catalase-positive organisms
Pathophysiology
- Defect in NADPH oxidase
- Therefore unable to generate superoxide radicals required by phagocytes to kill pathogens
Clinical Manifestations
- Recurrent infections
- Catalase-positive organisms, including Staphylococcus aureus, Burkholderia cepacia, Serratia marcescens, Nocardia, and Aspergillus
- CGD is the highest-risk group for invasive aspergillosis
- Granuloma formation, often in the GI and GU tracts and may precede other clinical symptoms
Differential Diagnosis
- Other primary immunodeficiencies
- MPO deficiency, which will have an abnormal DHR test but largely asymptomatic unless concurrent diabetes mellitus
- Hyper-IgE syndrome, though Aspergillus will be more typically pulmonary
- IRAK4/MyD88 deficiency, which won't have fungal infections and improves with age
- Humoral immunodeficiencies, such as CVID or Bruton tyrosine kinase deficiency, though they tend to have more infections with encapsulated organisms and will have abnormal quantitative immunoglobulins
- Inflammatory bowel disease
- Cystic fibrosis
- Sarcoidosis, which will cause granuloma formation but shouldn't increase risk of infection
Diagnosis
- The diagnosis is confirmed with the dihydrohodamine-123 (DHR-123) test
Management
- Treat intercurrent infections
- Prophylaxis with:
- TMP-SMX
- Itraconazole
- Possibly also interferon-γ
Further Reading
- Considerations in the Diagnosis of Chronic Granulomatous Disease. J Pediatric Infect Dis Soc. 2018;7(S1):S6-S11. doi: 10.1093/jpids/piy007